ruxolitinib

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:

• Navitoclax (BCL-XL/BCL-2 inhibitor)
• Pelabresib (BET inhibitor)
• Imetelstat (telomerase inhibitor)
• Luspatercept (erythroid maturation agent)
• Additional strategies

Presenter:  

Jacqueline S. Garcia, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to the full program here. https://bit.ly/47z8WCV

In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including:

• Overall approach to treatment
• Use of JAK inhibitors for treating myelofibrosis
• Treating patients with low platelets
• Defining JAK inhibitor failure
• Unmet needs in treatment and emerging therapeutic options, including momelotinib, luspatercept, ruxolitinib add-on therapy, and other phase III approaches

Presenters: 

John Mascarenhas, MD
Professor of Medicine

Icahn School of Medicine at Mount Sinai

Director, Adult Leukemia Program

Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute

New York, New York

Ruben A. Mesa, MD, FACP
Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Enterprise Senior Vice President, Atrium Health

President, Enterprise Cancer Service Line

Vice Dean for Cancer Programs, Wake Forest University School of Medicine

Professor of Medicine, Wake Forest University School of Medicine 

Winston-Salem, North Carolina

In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. 

The topics covered include:

• When to use cytoreduction therapies and which therapies to use in low-risk patients
• Type 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reports
• Experts’ thoughts on therapy options in higher-risk patients

Presenters:

Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Andrew Kuykendall, MD
Assistant Professor 
Department of Oncologic Sciences
University of South Florida
Assistant Member
Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, Florida
 

Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.

Link to the full program, including downloadable slides and an on-demand webcast from the live event:
bit.ly/3XF3cSF

In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include:

• Patient presentation and goals of frontline therapy
• Considerations for second-line therapy in the setting of treatment intolerance
• Experts’ thoughts on the potential of early intervention to alter disease progression

Presenters:

Raajit Rampal, MD, PhD
Associate Member
Associate Attending Physician
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.

Link to the full program, including downloadable slides and an on-demand webcast from the live event:
https://bit.ly/3X3x6jX

This podcast episode is part of a multimedia program discussing the co-management of moderate to severe atopic dermatitis (AD) in the primary care and specialty settings. Tune in to hear Dr Silverberg and NP Victoria Garcia-Albea highlight newly approved agents and the recent expanded labeling of an existing AD therapy, including: 

• Ruxolitinib, a topical JAK inhibitor for mild to moderate AD approved in 2021 
• Abrocitinib and upadacitinib, oral JAK inhibitors approved in early 2022 for moderate to severe AD
• Tralokinumab, an IL-13 inhibitor available as a subcutaneous injection, which was approved in late 2021 for moderate to severe AD
• Expanded approval for use in patients as young as 6 months for dupilumab, a subcutaneous IL-4 receptor α inhibitor

Presenters: 

Jonathan Silverberg, MD, PhD, MPH
Associate Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Victoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRN
Director
Lahey Dermatology Nurse Practitioner Training Program
Lahey Hospital and Medical Center
Burlington, Massachusetts

To view other program offerings, including a CE-certified recorded roundtable webcast, a ClinicalThought commentary, and to download slides, visit:
https://bit.ly/3PiupXZ

In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including:

• Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study 
• Analysis of an ongoing phase I/II trial of rilzabrutinib reporting safety and efficacy in the long-term extension for adult patients with relapsed/refractory ITP
• New data from the phase III HOPE-B study of etranacogene dezaparvovec gene therapy, using an AAV5-vector to deliver the Padua variant of the factor IX gene in patients with hemophilia B 
• An update from the phase I/II CLIMB THAL-111/SCD-121 studies reporting safety and efficacy on the first 10 patients receiving CTX001 with at least 3 months of follow-up
• Primary analysis from the phase III REACH3 trial evaluating ruxolitinib, an oral JAK1/2 inhibitor, in combination with steroids and calcineurin inhibitors, as a treatment for steroid-refractory or steroid-dependent chronic GVHD
• Top-line results from the phase II ROCKstar study of belumosudil, a ROCK2 kinase inhibitor, in patients with heavily pretreated chronic GVHD
• Phase I data from the GRAVITAS-119 study of JAK1 inhibitor itacitinib plus calcineurin inhibitors as prophylaxis treatment for acute GVHD

Presenters:

Hanny Al-Samkari, MD
Instructor
Department of Medicine
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

Sujit Sheth, MD
Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Mark A. Schroeder, MD
Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology. 

Link to full program, including downloadable slidesets, and on-demand Webcasts:
http://bit.ly/3tyQ9nG

In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:

• 3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 study
• A post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients
• 5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV study
• Phase II results of luspatercept for anemia in patients with myelofibrosis who are transfusion dependent
• Analysis of clinical benefit in patients with myelofibrosis and OS benefit from imetelstat.

Presenters:

Amy E. DeZern, MD, MHS
Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Srdan Verstovsek, MD, PhD
Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.

Link to full program and Capsule Summary downloadable slidesets:
http://bit.ly/3tyQ9nG